ERBB2 and breast cancer: HER2‐low breast cancer defined as immunohistochemistry (IHC) 1+ or IHC 2+ with a negative in situ hybridization (ISH) assay, which accounts for 45%–55% of breast cancer patients, is less likely to benefit from conventional HER2‐targeting drugs.